89bio, Inc.
NASDAQ Global MarketTotal Valuation
89bio, Inc. carries a market capitalization of 2.20B, placing it among publicly traded companies globally. Its enterprise value stands at 770.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.20B |
| Enterprise Value | 770.92M |
Share Statistics
89bio, Inc. currently has 148.30M shares outstanding.
| Shares Outstanding | 148.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.29 |
| P/TBV Ratio | 2.48 |
| P/FCF Ratio | -2.95 |
| P/OCF Ratio | -2.95 |
Financial Position
89bio, Inc. maintains a current ratio of 15.19, meaning it holds 15.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.21, indicating elevated leverage, while an interest coverage ratio of -78.17 demonstrates limited ability to service its debt obligations.
| Current Ratio | 15.19 |
| Quick Ratio | 14.17 |
| Debt / Equity | 7.21 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | -78.17 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -75.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.35M |
| Effective Tax Rate | N/A |
Stock Price Statistics
89bio, Inc.'s stock has gained approximately 65.0723% over the past 52 weeks. The 50-day moving average sits at 12.41, while the 200-day moving average is 9.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | 65.0723% |
| 50-Day Moving Average | 12.41 |
| 200-Day Moving Average | 9.75 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -465.64M, while operating income came in at -465.68M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -465.68M |
| Pretax Income | -448.85M |
| Net Income | -450.21M |
| EBITDA | -465.64M |
| EBIT | -465.68M |
| Earnings Per Share (EPS) | -3.42 |
Balance Sheet
89bio, Inc. holds 561.16M in cash and equivalents against 37.62M in total debt, resulting in a net debt position of -92.92M. Total book value stands at -1.01B, with working capital of 561.91M providing operational flexibility.
| Cash & Cash Equivalents | 561.16M |
| Total Debt | 37.62M |
| Net Debt | -92.92M |
| Equity (Book Value) | -1.01B |
| Book Value Per Share | -7.64 |
| Working Capital | 561.91M |
Cash Flow
89bio, Inc. produced -439.10M in operating cash flow over the past twelve months. After subtracting -72,000.00 in capital expenditures, free cash flow totaled -439.17M - equivalent to -3.33 per share.
| Operating Cash Flow | -439.10M |
| Capital Expenditures | -72,000.00 |
| Free Cash Flow | -439.17M |
| FCF Per Share | -3.33 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -35.48 |
| FCF Yield | -33.92 |
Scores
89bio, Inc. posts an Altman Z-Score of 5.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.73 |